Combined ethinylestradiol/gestodene contraceptive patch: Two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers

European Journal of Contraception and Reproductive Health Care

Volumn 9, Issue 3, 2004, Pages 173-181

  Heger Mahn, D ^a,d   Warlimont, C ^b   Faustmann, T ^b   Gerlinger, C ^b   Klipping, C ^c  

^a Dinox GmbH   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Medical Investigations   (Netherlands)

^d Dinox GmbH   (Germany)

Author keywords

Combined hormonal contraceptive; Contraceptive patch; Ethinylestradiol; Gestodene; Ovulation inhibition; Transdermal administration; Transvaginal ultrasound; User acceptability

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; LUTEINIZING HORMONE; PROGESTERONE;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE RELEASE; MASTALGIA; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; OVARY FUNCTION; OVULATION; OVULATION INHIBITION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; SCORING SYSTEM; SIDE EFFECT; TRANSVAGINAL ECHOGRAPHY;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; GERMANY; HUMANS; MENSTRUAL CYCLE; NETHERLANDS; NORPREGNENES; OVULATION INHIBITION; PATIENT COMPLIANCE; SAFETY; TREATMENT OUTCOME;

EID: 9144244439     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180400008940     Document Type: Article

References (21)

1. Food and Drug Administration. Oral Contraceptives and Thromboembolic Disorders, Current Drug Information. FDA, 1970; April 24
2. Apelo R, Veloso I. Clinical experience with ethinylestradiol and D-norgestrel as an oral contraceptive. Fertil Steril 1975;26:283-8
3. Nevinny Stickel J. German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestradiol. Acta Obstet Gynecol Scand Suppl 1987;144:19-21
4. Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg. Eur J Contracept Reprod Health Care 1999;4(Suppl 2):9-15
5. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215
6. Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and contraception: a review. Contraception 1995;52:137-41
7. Ory HW. The noncontraceptive health benefits from oral contraceptives. Fam Plann Perspect 1982;14:182-4
8. Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996;1: 275-84
9. Kubba A, Guillebaud J, Anderson RA, et al. Contraception. Lancet 2000;356:1913-19
10. Turgeon JL, McDonnell DP, Martin KA, et al. Hormone therapy: physiological complexity belies therapeutic simplicity Science 2004;304:1269-73
11. Jewelewicz R. New developments in topical estrogen therapy. Fertil Steril 1997;67:1-12
12. Cheang A, Sitruk-Ware R, Utian WH. A risk-benefit appraisal of transdermal estrogen therapy. Drug Safety 1993;9:365-79
13. Balfour JA, Heel RC. Transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-82
14. Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. Br Med J 1997;315:288
15. TM versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril 2003;80:34-42
16. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215
17. Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995;50:364-95
18. Committee on Safety of Medicines/Medicines Control Agency. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Current Problems 1999;25:12
19. Reuss ML, Kolton S, Tharakan T. Transvaginal ultrasonography in gynecologic office practice: assessment in 663 premenopausal women. Am J Obstet Gynecol 1996; 175:1189-94
20. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583-90
21. Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003;17: 107-14